25 XP   0   0   10

Orchid Pharma Limited
Buy, Hold or Sell?

Let's analyse Orchid Pharma Limited together

PenkeI guess you are interested in Orchid Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Orchid Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Orchid Pharma Limited

I send you an email if I find something interesting about Orchid Pharma Limited.

Quick analysis of Orchid Pharma Limited (30 sec.)










What can you expect buying and holding a share of Orchid Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR135.78
Expected worth in 1 year
INR168.32
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
INR32.55
Return On Investment
3.0%

For what price can you sell your share?

Current Price per Share
INR1,084.35
Expected price per share
INR948.70 - INR1,360
How sure are you?
50%

1. Valuation of Orchid Pharma Limited (5 min.)




Live pricePrice per Share (EOD)

INR1,084.35

Intrinsic Value Per Share

INR-250.52 - INR132.11

Total Value Per Share

INR-114.74 - INR267.89

2. Growth of Orchid Pharma Limited (5 min.)




Is Orchid Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$82.6m$77.6m$4.9m6.0%

How much money is Orchid Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$5.5m-$234.1k$5.7m104.2%
Net Profit Margin7.0%-0.3%--

How much money comes from the company's main activities?

3. Financial Health of Orchid Pharma Limited (5 min.)




What can you expect buying and holding a share of Orchid Pharma Limited? (5 min.)

Welcome investor! Orchid Pharma Limited's management wants to use your money to grow the business. In return you get a share of Orchid Pharma Limited.

What can you expect buying and holding a share of Orchid Pharma Limited?

First you should know what it really means to hold a share of Orchid Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Orchid Pharma Limited is INR1,084. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Orchid Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Orchid Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR135.78. Based on the TTM, the Book Value Change Per Share is INR8.14 per quarter. Based on the YOY, the Book Value Change Per Share is INR-1.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Orchid Pharma Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.110.0%0.110.0%0.000.0%-0.050.0%-0.220.0%
Usd Book Value Change Per Share0.100.0%0.100.0%-0.010.0%0.540.0%-0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.100.0%0.100.0%-0.010.0%0.540.0%-0.050.0%
Usd Price Per Share4.60-4.60-3.42-7.40-4.62-
Price to Earnings Ratio41.97-41.97--741.34--160.91--100.57-
Price-to-Total Gains Ratio47.10-47.10--261.67--7.02--4.39-
Price to Book Ratio2.82-2.82-2.23-4.76-2.98-
Price-to-Total Gains Ratio47.10-47.10--261.67--7.02--4.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.0122
Number of shares76
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.100.54
Usd Total Gains Per Share0.100.54
Gains per Quarter (76 shares)7.4241.00
Gains per Year (76 shares)29.68164.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1030200164154
2059500328318
3089800492482
401191100656646
501481400820810
601781700984974
70208200011481138
80237230013121302
90267260014761466
100297290016401630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%2.06.00.025.0%9.07.00.056.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%4.04.00.050.0%11.05.00.068.8%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%8.00.08.050.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%4.04.00.050.0%11.05.00.068.8%

Fundamentals of Orchid Pharma Limited

About Orchid Pharma Limited

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.

Fundamental data was last updated by Penke on 2024-04-14 05:51:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Orchid Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Orchid Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 7.0% means that ₹0.07 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Orchid Pharma Limited:

  • The MRQ is 7.0%. The company is making a profit. +1
  • The TTM is 7.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.0%TTM7.0%0.0%
TTM7.0%YOY-0.3%+7.3%
TTM7.0%5Y-6.7%+13.7%
5Y-6.7%10Y-22.3%+15.6%
1.1.2. Return on Assets

Shows how efficient Orchid Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.8% Return on Assets means that Orchid Pharma Limited generated ₹0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Orchid Pharma Limited:

  • The MRQ is 3.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.8%TTM3.8%0.0%
TTM3.8%YOY-0.2%+4.0%
TTM3.8%5Y-2.2%+6.0%
5Y-2.2%10Y-5.5%+3.3%
1.1.3. Return on Equity

Shows how efficient Orchid Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.7% Return on Equity means Orchid Pharma Limited generated ₹0.07 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Orchid Pharma Limited:

  • The MRQ is 6.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.7%TTM6.7%0.0%
TTM6.7%YOY-0.3%+7.0%
TTM6.7%5Y-4.8%+11.6%
5Y-4.8%10Y-74.2%+69.3%

1.2. Operating Efficiency of Orchid Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Orchid Pharma Limited is operating .

  • Measures how much profit Orchid Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 7.2% means the company generated ₹0.07  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Orchid Pharma Limited:

  • The MRQ is 7.2%. The company is operating less efficient.
  • The TTM is 7.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY-4.5%+11.8%
TTM7.2%5Y-10.9%+18.1%
5Y-10.9%10Y-12.1%+1.2%
1.2.2. Operating Ratio

Measures how efficient Orchid Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.76 means that the operating costs are ₹0.76 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Orchid Pharma Limited:

  • The MRQ is 0.758. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.758. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.758TTM0.7580.000
TTM0.758YOY1.058-0.300
TTM0.7585Y1.062-0.304
5Y1.06210Y1.068-0.006

1.3. Liquidity of Orchid Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Orchid Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.35 means the company has ₹1.35 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Orchid Pharma Limited:

  • The MRQ is 1.347. The company is just able to pay all its short-term debts.
  • The TTM is 1.347. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.347TTM1.3470.000
TTM1.347YOY1.868-0.521
TTM1.3475Y2.126-0.779
5Y2.12610Y1.559+0.567
1.3.2. Quick Ratio

Measures if Orchid Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.69 means the company can pay off ₹0.69 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Orchid Pharma Limited:

  • The MRQ is 0.686. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.686. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.686TTM0.6860.000
TTM0.686YOY1.129-0.443
TTM0.6865Y1.461-0.775
5Y1.46110Y1.006+0.454

1.4. Solvency of Orchid Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Orchid Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Orchid Pharma Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.44 means that Orchid Pharma Limited assets are financed with 43.8% credit (debt) and the remaining percentage (100% - 43.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Orchid Pharma Limited:

  • The MRQ is 0.438. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.438. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.438TTM0.4380.000
TTM0.438YOY0.417+0.021
TTM0.4385Y0.592-0.154
5Y0.59210Y0.790-0.197
1.4.2. Debt to Equity Ratio

Measures if Orchid Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 77.9% means that company has ₹0.78 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Orchid Pharma Limited:

  • The MRQ is 0.779. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.779. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.779TTM0.7790.000
TTM0.779YOY0.715+0.064
TTM0.7795Y0.614+0.165
5Y0.61410Y10.102-9.488

2. Market Valuation of Orchid Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Orchid Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Orchid Pharma Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 41.97 means the investor is paying ₹41.97 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Orchid Pharma Limited:

  • The EOD is 118.738. Based on the earnings, the company is expensive. -2
  • The MRQ is 41.966. Based on the earnings, the company is overpriced. -1
  • The TTM is 41.966. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD118.738MRQ41.966+76.771
MRQ41.966TTM41.9660.000
TTM41.966YOY-741.343+783.309
TTM41.9665Y-160.906+202.872
5Y-160.90610Y-100.567-60.339
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Orchid Pharma Limited:

  • The EOD is -82.914. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -29.305. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -29.305. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-82.914MRQ-29.305-53.609
MRQ-29.305TTM-29.3050.000
TTM-29.305YOY18.528-47.833
TTM-29.3055Y104.244-133.549
5Y104.24410Y65.173+39.071
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Orchid Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.82 means the investor is paying ₹2.82 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Orchid Pharma Limited:

  • The EOD is 7.986. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.823. Based on the equity, the company is underpriced. +1
  • The TTM is 2.823. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.986MRQ2.823+5.164
MRQ2.823TTM2.8230.000
TTM2.823YOY2.234+0.588
TTM2.8235Y4.761-1.939
5Y4.76110Y2.979+1.782
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Orchid Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--8.1378.1370%-1.090+113%44.955-82%-3.775+146%
Book Value Per Share--135.777135.7770%127.640+6%85.668+58%37.675+260%
Current Ratio--1.3471.3470%1.868-28%2.126-37%1.559-14%
Debt To Asset Ratio--0.4380.4380%0.417+5%0.592-26%0.790-45%
Debt To Equity Ratio--0.7790.7790%0.715+9%0.614+27%10.102-92%
Dividend Per Share----0%-0%-0%-0%
Eps--9.1329.1320%-0.385+104%-4.237+146%-18.505+303%
Free Cash Flow Per Share---13.078-13.0780%15.393-185%3.214-507%9.412-239%
Free Cash Flow To Equity Per Share---6.933-6.9330%-27.352+295%-16.255+134%-11.547+67%
Gross Profit Margin--0.6900.6900%12.409-94%3.227-79%2.400-71%
Intrinsic Value_10Y_max--132.112--------
Intrinsic Value_10Y_min---250.522--------
Intrinsic Value_1Y_max--10.260--------
Intrinsic Value_1Y_min---4.670--------
Intrinsic Value_3Y_max--33.097--------
Intrinsic Value_3Y_min---31.813--------
Intrinsic Value_5Y_max--58.671--------
Intrinsic Value_5Y_min---78.236--------
Market Cap54997256085.000+65%19438095075.00019438095075.0000%14465087320.000+34%31299666526.565-38%19566070886.595-1%
Net Profit Margin--0.0700.0700%-0.003+105%-0.067+196%-0.223+421%
Operating Margin--0.0720.0720%-0.045+163%-0.109+250%-0.121+267%
Operating Ratio--0.7580.7580%1.058-28%1.062-29%1.068-29%
Pb Ratio7.986+65%2.8232.8230%2.234+26%4.761-41%2.979-5%
Pe Ratio118.738+65%41.96641.9660%-741.343+1867%-160.906+483%-100.567+340%
Price Per Share1084.350+65%383.250383.2500%285.200+34%616.295-38%385.227-1%
Price To Free Cash Flow Ratio-82.914-183%-29.305-29.3050%18.528-258%104.244-128%65.173-145%
Price To Total Gains Ratio133.265+65%47.10147.1010%-261.674+656%-7.021+115%-4.389+109%
Quick Ratio--0.6860.6860%1.129-39%1.461-53%1.006-32%
Return On Assets--0.0380.0380%-0.002+105%-0.022+159%-0.055+246%
Return On Equity--0.0670.0670%-0.003+104%-0.048+172%-0.742+1203%
Total Gains Per Share--8.1378.1370%-1.090+113%44.955-82%-3.775+146%
Usd Book Value--82637880.00082637880.0000%77685588.000+6%55422156.000+49%17683135.500+367%
Usd Book Value Change Per Share--0.0980.0980%-0.013+113%0.539-82%-0.045+146%
Usd Book Value Per Share--1.6291.6290%1.532+6%1.028+58%0.452+260%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.1100.1100%-0.005+104%-0.051+146%-0.222+303%
Usd Free Cash Flow---7959624.000-7959624.0000%9368532.000-185%2800351.200-384%9583174.500-183%
Usd Free Cash Flow Per Share---0.157-0.1570%0.185-185%0.039-507%0.113-239%
Usd Free Cash Flow To Equity Per Share---0.083-0.0830%-0.328+295%-0.195+134%-0.139+67%
Usd Market Cap659967073.020+65%233257140.900233257140.9000%173581047.840+34%375595998.319-38%234792850.639-1%
Usd Price Per Share13.012+65%4.5994.5990%3.422+34%7.396-38%4.623-1%
Usd Profit--5558196.0005558196.0000%-234144.000+104%-3211802.400+158%-18842964.000+439%
Usd Revenue--79907808.00079907808.0000%67146888.000+19%66804890.400+20%77046954.000+4%
Usd Total Gains Per Share--0.0980.0980%-0.013+113%0.539-82%-0.045+146%
 EOD+5 -3MRQTTM+0 -0YOY+23 -115Y+19 -1510Y+24 -10

3.2. Fundamental Score

Let's check the fundamental score of Orchid Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15118.738
Price to Book Ratio (EOD)Between0-17.986
Net Profit Margin (MRQ)Greater than00.070
Operating Margin (MRQ)Greater than00.072
Quick Ratio (MRQ)Greater than10.686
Current Ratio (MRQ)Greater than11.347
Debt to Asset Ratio (MRQ)Less than10.438
Debt to Equity Ratio (MRQ)Less than10.779
Return on Equity (MRQ)Greater than0.150.067
Return on Assets (MRQ)Greater than0.050.038
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Orchid Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.975
Ma 20Greater thanMa 501,094.880
Ma 50Greater thanMa 1001,096.689
Ma 100Greater thanMa 200913.060
OpenGreater thanClose1,102.400
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
EBIT  -1,306,24036,242-1,269,998811,306-458,692204,694-253,998736,620482,622
Operating Income  -1,306,240584,490-721,750216,806-504,944166,045-338,899628,825289,926



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets12,252,063
Total Liabilities5,365,573
Total Stockholder Equity6,886,490
 As reported
Total Liabilities 5,365,573
Total Stockholder Equity+ 6,886,490
Total Assets = 12,252,063

Assets

Total Assets12,252,063
Total Current Assets5,010,097
Long-term Assets7,241,966
Total Current Assets
Cash And Cash Equivalents 225,971
Short-term Investments 81,875
Net Receivables 2,161,475
Inventory 2,287,380
Other Current Assets 253,396
Total Current Assets  (as reported)5,010,097
Total Current Assets  (calculated)5,010,097
+/-0
Long-term Assets
Property Plant Equipment 6,191,719
Intangible Assets 3,857
Long-term Assets Other 20,214
Long-term Assets  (as reported)7,241,966
Long-term Assets  (calculated)6,215,790
+/- 1,026,176

Liabilities & Shareholders' Equity

Total Current Liabilities3,718,917
Long-term Liabilities1,646,656
Total Stockholder Equity6,886,490
Total Current Liabilities
Short-term Debt 1,825,081
Short Long Term Debt 1,825,081
Accounts payable 1,817,850
Other Current Liabilities 41,126
Total Current Liabilities  (as reported)3,718,917
Total Current Liabilities  (calculated)5,509,138
+/- 1,790,221
Long-term Liabilities
Long term Debt 1,488,376
Long-term Liabilities  (as reported)1,646,656
Long-term Liabilities  (calculated)1,488,376
+/- 158,280
Total Stockholder Equity
Common Stock408,164
Retained Earnings -22,682,405
Accumulated Other Comprehensive Income 23,830,339
Other Stockholders Equity 5,330,392
Total Stockholder Equity (as reported)6,886,490
Total Stockholder Equity (calculated)6,886,490
+/-0
Other
Capital Stock408,164
Cash and Short Term Investments 307,846
Common Stock Shares Outstanding 40,816
Current Deferred Revenue34,860
Liabilities and Stockholders Equity 12,252,063
Net Debt 3,087,486
Net Invested Capital 10,199,947
Net Working Capital 1,291,180
Property Plant and Equipment Gross 6,191,719
Short Long Term Debt Total 3,313,457



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-31
> Total Assets 
18,124,829
21,685,316
28,910,132
34,842,295
42,339,553
37,735,624
40,705,019
39,863,613
0
40,613,951
38,620,721
33,579,969
31,253,694
30,770,350
17,216,558
12,372,521
11,105,625
12,252,063
12,252,06311,105,62512,372,52117,216,55830,770,35031,253,69433,579,96938,620,72140,613,951039,863,61340,705,01937,735,62442,339,55334,842,29528,910,13221,685,31618,124,829
   > Total Current Assets 
7,002,630
9,078,965
12,324,831
13,233,449
15,953,589
17,005,122
17,157,697
13,403,106
0
12,781,206
12,511,978
8,791,356
6,789,446
6,976,566
5,872,157
5,498,571
4,498,858
5,010,097
5,010,0974,498,8585,498,5715,872,1576,976,5666,789,4468,791,35612,511,97812,781,206013,403,10617,157,69717,005,12215,953,58913,233,44912,324,8319,078,9657,002,630
       Cash And Cash Equivalents 
256,946
162,591
1,189,247
310,390
525,068
3,351,574
2,223,415
1,785,952
0
3,905,650
3,149,401
2,570,640
351,130
923,109
898,915
156,939
43,066
225,971
225,97143,066156,939898,915923,109351,1302,570,6403,149,4013,905,65001,785,9522,223,4153,351,574525,068310,3901,189,247162,591256,946
       Short-term Investments 
659,199
945,994
1,186,313
1,050,839
1,020,571
2,057,337
3,623,245
0
0
0
0
0
2,704,395
2,332,079
122
158,208
5,204
81,875
81,8755,204158,2081222,332,0792,704,395000003,623,2452,057,3371,020,5711,050,8391,186,313945,994659,199
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
1,216,705
1,323,395
3,326,167
3,584,713
2,665,155
2,161,475
2,161,4752,665,1553,584,7133,326,1671,323,3951,216,705000000000000
       Inventory 
4,005,636
4,481,495
6,116,133
6,491,545
7,682,538
4,226,392
6,176,251
6,687,254
0
2,519,280
2,418,491
2,112,513
1,937,382
1,697,721
1,557,093
1,528,853
1,726,563
2,287,380
2,287,3801,726,5631,528,8531,557,0931,697,7211,937,3822,112,5132,418,4912,519,28006,687,2546,176,2514,226,3927,682,5386,491,5456,116,1334,481,4954,005,636
       Other Current Assets 
2,080,849
3,488,885
3,833,138
5,380,675
6,725,412
7,369,819
5,134,786
4,929,900
0
6,356,276
6,944,086
4,108,203
1,796,539
700,262
89,860
69,858
58,870
253,396
253,39658,87069,85889,860700,2621,796,5394,108,2036,944,0866,356,27604,929,9005,134,7867,369,8196,725,4125,380,6753,833,1383,488,8852,080,849
   > Long-term Assets 
11,122,199
12,606,351
16,585,301
21,608,846
26,385,964
20,730,502
23,547,322
26,460,507
0
27,832,745
26,108,743
24,788,613
24,464,248
23,793,784
11,344,401
6,873,950
6,606,767
7,241,966
7,241,9666,606,7676,873,95011,344,40123,793,78424,464,24824,788,61326,108,74327,832,745026,460,50723,547,32220,730,50226,385,96421,608,84616,585,30112,606,35111,122,199
       Property Plant Equipment 
10,346,553
11,474,417
15,100,104
20,105,701
24,048,657
19,490,946
22,064,895
20,173,882
0
16,640,110
15,125,087
16,500,243
15,255,370
19,265,037
10,987,722
6,775,074
6,048,191
6,191,719
6,191,7196,048,1916,775,07410,987,72219,265,03715,255,37016,500,24315,125,08716,640,110020,173,88222,064,89519,490,94624,048,65720,105,70115,100,10411,474,41710,346,553
       Goodwill 
454,424
728,739
948,232
948,232
948,232
948,232
986,125
0
0
0
0
0
948,232
948,232
0
0
0
0
0000948,232948,23200000986,125948,232948,232948,232948,232728,739454,424
       Intangible Assets 
320,235
402,358
536,128
546,794
545,157
283,205
488,183
0
0
0
0
0
373,714
351,519
286,344
3,686
3,373
3,857
3,8573,3733,686286,344351,519373,71400000488,183283,205545,157546,794536,128402,358320,235
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
7,876,225
7,746,841
66,953
91,013
216,915
0
0216,91591,01366,9537,746,8417,876,225000000000000
> Total Liabilities 
13,516,956
13,929,446
24,059,110
28,192,495
36,001,573
28,359,025
29,993,344
28,029,923
0
37,320,094
38,130,272
37,456,629
39,171,291
37,810,725
6,972,985
5,843,443
4,631,826
5,365,573
5,365,5734,631,8265,843,4436,972,98537,810,72539,171,29137,456,62938,130,27237,320,094028,029,92329,993,34428,359,02536,001,57328,192,49524,059,11013,929,44613,516,956
   > Total Current Liabilities 
2,723,650
2,679,258
6,647,476
7,338,009
8,558,339
9,718,323
9,502,155
15,047,107
0
11,226,619
13,376,175
15,407,175
20,125,125
23,433,453
1,808,162
1,420,818
2,407,783
3,718,917
3,718,9172,407,7831,420,8181,808,16223,433,45320,125,12515,407,17513,376,17511,226,619015,047,1079,502,1559,718,3238,558,3397,338,0096,647,4762,679,2582,723,650
       Short-term Debt 
0
0
0
0
0
0
0
6,470,604
0
6,466,416
6,337,907
10,459,645
13,080,424
18,053,493
624,224
252,426
597,884
1,825,081
1,825,081597,884252,426624,22418,053,49313,080,42410,459,6456,337,9076,466,41606,470,6040000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
13,080,424
18,053,493
624,224
252,426
597,884
1,825,081
1,825,081597,884252,426624,22418,053,49313,080,424000000000000
       Accounts payable 
2,212,534
1,992,395
2,217,704
2,759,522
3,846,834
2,957,900
3,364,381
4,006,637
0
0
8,261
8,351
3,587,934
3,024,469
1,034,351
1,099,524
1,676,830
1,817,850
1,817,8501,676,8301,099,5241,034,3513,024,4693,587,9348,3518,261004,006,6373,364,3812,957,9003,846,8342,759,5222,217,7041,992,3952,212,534
       Other Current Liabilities 
511,116
686,863
4,429,772
4,578,487
4,711,505
6,760,423
6,137,774
4,569,866
0
4,760,203
7,030,007
4,939,179
3,456,767
75,279
62,114
7,961
9,839
41,126
41,1269,8397,96162,11475,2793,456,7674,939,1797,030,0074,760,20304,569,8666,137,7746,760,4234,711,5054,578,4874,429,772686,863511,116
   > Long-term Liabilities 
10,793,306
11,250,188
17,411,634
20,854,486
27,443,234
18,640,702
20,491,189
12,982,816
0
26,093,475
24,754,097
22,049,454
19,046,166
14,377,272
5,164,823
4,422,625
2,224,043
1,646,656
1,646,6562,224,0434,422,6255,164,82314,377,27219,046,16622,049,45424,754,09726,093,475012,982,81620,491,18918,640,70227,443,23420,854,48617,411,63411,250,18810,793,306
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
107,097
109,226
150,116
147,651
142,391
0
0142,391147,651150,116109,226107,097000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
97,564
96,165
0
0
0
0
000096,16597,564000000000000
> Total Stockholder Equity
4,607,861
7,755,870
4,851,022
6,649,800
6,337,980
9,376,599
10,692,442
11,805,462
0
3,293,857
490,449
-3,876,660
-7,917,597
-7,040,375
10,243,573
6,529,078
6,473,799
6,886,490
6,886,4906,473,7996,529,07810,243,573-7,040,375-7,917,597-3,876,660490,4493,293,857011,805,46210,692,4429,376,5996,337,9806,649,8004,851,0227,755,8704,607,861
   Common Stock
341,319
646,182
658,163
658,508
704,421
704,421
704,421
704,421
0
0
889,643
889,643
889,643
889,643
408,164
408,164
408,164
408,164
408,164408,164408,164408,164889,643889,643889,643889,64300704,421704,421704,421704,421658,508658,163646,182341,319
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,063,721
21,092,266
23,878,503
23,830,339
23,830,33923,878,50321,092,26621,063,72100000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
4,266,542
7,109,688
4,192,859
5,991,292
5,633,559
8,672,178
9,988,021
11,101,041
0
10,687,781
9,785,856
10,323,661
10,594,285
10,768,388
7,914,117
5,330,392
5,330,392
5,330,392
5,330,3925,330,3925,330,3927,914,11710,768,38810,594,28510,323,6619,785,85610,687,781011,101,0419,988,0218,672,1785,633,5595,991,2924,192,8597,109,6884,266,542



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue6,658,984
Cost of Revenue-3,846,207
Gross Profit2,812,7772,812,777
 
Operating Income (+$)
Gross Profit2,812,777
Operating Expense-1,201,372
Operating Income289,9261,611,405
 
Operating Expense (+$)
Research Development63,621
Selling General Administrative87,865
Selling And Marketing Expenses143,363
Operating Expense1,201,372294,849
 
Net Interest Income (+$)
Interest Income6,180
Interest Expense-322,257
Other Finance Cost-6,180
Net Interest Income-322,257
 
Pretax Income (+$)
Operating Income289,926
Net Interest Income-322,257
Other Non-Operating Income Expenses0
Income Before Tax (EBT)552,46948,918
EBIT - interestExpense = 160,365
723,630
785,440
Interest Expense322,257
Earnings Before Interest and Taxes (EBIT)482,622874,726
Earnings Before Interest and Taxes (EBITDA)1,030,490
 
After tax Income (+$)
Income Before Tax552,469
Tax Provision-0
Net Income From Continuing Ops530,934552,469
Net Income463,183
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses5,047,579
Total Other Income/Expenses Net241,008322,257
 

Technical Analysis of Orchid Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Orchid Pharma Limited. The general trend of Orchid Pharma Limited is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Orchid Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Orchid Pharma Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,220 < 1,360.

The bearish price targets are: 1,037 > 952.10 > 948.70.

Tweet this
Orchid Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Orchid Pharma Limited. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Orchid Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Orchid Pharma Limited. The current macd is 3.12944097.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Orchid Pharma Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Orchid Pharma Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Orchid Pharma Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Orchid Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartOrchid Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Orchid Pharma Limited. The current adx is 16.80.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Orchid Pharma Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Orchid Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Orchid Pharma Limited. The current sar is 1,172.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Orchid Pharma Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Orchid Pharma Limited. The current rsi is 50.97. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Orchid Pharma Limited Daily Relative Strength Index (RSI) ChartOrchid Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Orchid Pharma Limited. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Orchid Pharma Limited price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Orchid Pharma Limited Daily Stochastic Oscillator ChartOrchid Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Orchid Pharma Limited. The current cci is -4.92954567.

Orchid Pharma Limited Daily Commodity Channel Index (CCI) ChartOrchid Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Orchid Pharma Limited. The current cmo is 0.15013727.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Orchid Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartOrchid Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Orchid Pharma Limited. The current willr is -74.16621104.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Orchid Pharma Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Orchid Pharma Limited Daily Williams %R ChartOrchid Pharma Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Orchid Pharma Limited.

Orchid Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Orchid Pharma Limited. The current atr is 55.82.

Orchid Pharma Limited Daily Average True Range (ATR) ChartOrchid Pharma Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Orchid Pharma Limited. The current obv is 10,331,587.

Orchid Pharma Limited Daily On-Balance Volume (OBV) ChartOrchid Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Orchid Pharma Limited. The current mfi is 41.13.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Orchid Pharma Limited Daily Money Flow Index (MFI) ChartOrchid Pharma Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Orchid Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Orchid Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Orchid Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.975
Ma 20Greater thanMa 501,094.880
Ma 50Greater thanMa 1001,096.689
Ma 100Greater thanMa 200913.060
OpenGreater thanClose1,102.400
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Orchid Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Orchid Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Orchid Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Orchid Pharma Limited

I send you an email if I find something interesting about Orchid Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Orchid Pharma Limited.

Receive notifications about Orchid Pharma Limited in your mailbox!